Efficacy and Safety of Oral Antidiabetic Drugs in Comparison to Insulin in Treating Gestational Diabetes Mellitus: A Meta-Analysis
Open accessThe DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To assess the efficacy and safety of oral antidiabetic drugs (OADs) in gestational diabetes mellitus (GDM) in comparison to insulin. METHODS: A meta-analysis of randomized controlled trials was conducted. The efficacy and safety of OADs in comparison to insulin in GDM patients were explored. Studies were identified by conducting a literature search using the electronic databases of Medline, CENTRAL, CINAHL, LILACS, Scopus and Web of Science in addition to conducting hand search of relevant journals from inception until October 2013. RESULTS: Thirteen studies involving 2,151 patients met the inclusion criteria. These studies were randomized controlled trials of metformin and glyburide in comparison to insulin therapy. Our results indicated a significant increase in the risk for preterm births (RR, 1.51; 95% CI, 1.04-2.19, p = 0.03) with metformin compared to insulin. However, a significant decrease in the risk for gestational hypertension (RR, 0.54; 95% CI, 0.31-0.91, p = 0.02) was found. Postprandial glucose levels also decreased significantly in patients receiving metformin (MD, -2.47 mg/dL; 95% CI, -4.00, -0.94, p = 0.002). There was no significant difference between the two groups for the remaining outcomes. There were significant increases in the risks of macrosomia (RR, 2.34; 95% CI, 1.18-4.63, p = 0.03) and neonatal hypoglycemia (RR, 2.06; 95% CI, 1.27-3.34, p = 0.005) in the glyburide group compared to insulin whereas results for the other analyzed outcomes remained non-significant. CONCLUSION: The available evidence suggests favorable effects of metformin in treating GDM patients. Metformin seems to be an efficacious alternative to insulin and a better choice than glyburide especially those with mild form of disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures









Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The HAPO study confirmed findings in Pima Indians1409 that, even among offspring of women without GDM as it is currently defined, there is a linear association between maternal glucose concentration during pregnancy and newborn weight, rates of large-for-gestational-age, and cesarean delivery.64,1418–1421”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1421]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Both low and high birth weight are associated with higher rates of DM.1421”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1421]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & The PRISMA Group (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000097 · Cited by 64,042 · cited 1×
“We conducted this meta-analysis according to Cochrane Handbook for Systematic Reviews of Interventions [17], and data are presented according to the recommendations of PRISMA statement [18].”
MethodBias in meta-analysis detected by a simple, graphical test
Egger, M., Smith, G. D., Schneider, M., & Minder, C. (1997) · BMJ · doi:10.1136/bmj.315.7109.629 · Cited by 56,722 · cited 1×
“We assessed reporting bias by using Egger’s test [19] in case five or more studies were included for an outcome.”
MethodPreferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
(2009) · PubMed Central · Cited by 44,859
Diagnosis and Classification of Diabetes Mellitus
American Diabetes Association (2011) · Diabetes Care · doi:10.2337/dc11-s062 · Cited by 13,988
Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1. The Cochrane Collaboration
Higgins, J. P. T., Green, S. R., & Higgins, J. P. T. (2008) · Cited by 7,171
Hyperglycemia and adverse pregnancy outcomes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0707943 · Cited by 5,563
Bellamy, L., Casas, J.-P., Hingorani, A. D., & Williams, D. J. (2007) · BMJ · doi:10.1136/bmj.39335.385301.be · Cited by 2,552
Gestational Diabetes and the Incidence of Type 2 Diabetes
Kim, C., Newton, K. M., & Knopp, R. H. (2002) · Diabetes Care · doi:10.2337/diacare.25.10.1862 · Cited by 2,276 · cited 1×
“Normally, GDM ends at the termination of pregnancy; however, such patients are at a higher risk for development of type 2 diabetes mellitus later in their life [2].”
BackgroundDiagnosis and classification of diabetes mellitus
American Diabetes Association (2013) · Diabetes Care · doi:10.2337/dc13-s067 · Cited by 2,245
Cellular and molecular mechanisms of metformin: an overview
Viollet, B., Guigas, B., Garcia, N. S., Leclerc, J., Foretz, M., & Andreelli, F. (2012) · Clinical Science · doi:10.1042/cs20110386 · Cited by 1,720 · cited 1×
“A decreased risk for gestational hypertension may have resulted from decreased inflammatory response and decreased insulin resistance via complex actions of metformin on maternal endothelial cell [41].”
BackgroundMetformin versus insulin for the treatment of gestational diabetes
Rowan, J. A., Hague, W. M., Gao, W., Battin, M. R., & Moore, M. P. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0707193 · Cited by 1,291 · cited 2×
“Incidence of preterm births reported with metformin use in some of the studies were mostly at 33–35 week of gestation [20,23] which may be an acceptable risk comparing adverse outcomes of hyperglycemia during pregnancy especially in a situation e.”
BackgroundA comparison of glyburide and insulin in women with gestational diabetes mellitus
Langer, O., Conway, D. L., Berkus, M. D., Xenakis, E. M.-J., & Gonzales, O. (2000) · New England Journal of Medicine · doi:10.1056/nejm200010193431601 · Cited by 924 · cited 2×
“[29] did not detect glyburide in cord serum of infants born to GDM mothers receiving glyburide, apprehensions still exist about the transfer of drug across the placenta even in minimal quantities [39], and also in a recent pharmacokinetic study in GDM patients wherein umbilical cord concentration of drug averaged 70%…”
ResultGestational diabetes: The consequences of not treating
Langer, O., Yogev, Y., Most, O., & Xenakis, E. M. J. (2005) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2004.11.039 · Cited by 677 · cited 2×
“It increases the risk of macrosomia, large for gestational age (LGA) births, shoulder dystocia, birth trauma, neonatal hypoglycemia, preterm births, hyperbilirubinemia and intrauterine growth retardation [3–7].”
BackgroundChildhood Obesity and Metabolic Imprinting
Hillier, T. A., Pedula, K. L., Schmidt, M. M., Mullen, J. A., Charles, M.-A., & Pettitt, D. J. (2007) · Diabetes Care · doi:10.2337/dc06-2361 · Cited by 656
Gestational diabetes: the need for a common ground
Reece, E. A., Leguizamón, G., & Wiznitzer, A. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60515-8 · Cited by 589 · cited 2×
“It increases the risk of macrosomia, large for gestational age (LGA) births, shoulder dystocia, birth trauma, neonatal hypoglycemia, preterm births, hyperbilirubinemia and intrauterine growth retardation [3–7].”
BackgroundWEIGHT AND LENGTH AT BIRTH OF INFANTS OF DIABETIC MOTHERS
Pedersen, J. (1954) · Acta Endocrinologica · doi:10.1530/acta.0.0160330 · Cited by 494 · cited 1×
“Maternal hyperglycemia is mainly linked with increased risk of large babies and neonatal hypoglycemia, but in our study the difference between the two groups remained nonsignificant for maternal glycemic levels [44,45].”
BackgroundThe macrosomic fetus: a challenge in current obstetrics
HENRIKSEN, T. (2008) · Acta Obstetricia et Gynecologica Scandinavica · doi:10.1080/00016340801899289 · Cited by 454 · cited 2×
“It increases the risk of macrosomia, large for gestational age (LGA) births, shoulder dystocia, birth trauma, neonatal hypoglycemia, preterm births, hyperbilirubinemia and intrauterine growth retardation [3–7].”
BackgroundPregnancy outcomes among women with polycystic ovary syndrome treated with metformin
Glueck, C. J., Wang, P., Goldenberg, N., & Sieve-Smith, L. (2002) · Human Reproduction · doi:10.1093/humrep/17.11.2858 · Cited by 385 · cited 1×
“Since metformin is not known to be teratogenic, it becomes an OAD of interest for use in GDM [37,38].”
BackgroundPregnancy outcome after first-trimester exposure to metformin: a meta-analysis
Gilbert, C., Valois, M., & Koren, G. (2006) · Fertility and Sterility · doi:10.1016/j.fertnstert.2006.02.098 · Cited by 274 · cited 1×
“Since metformin is not known to be teratogenic, it becomes an OAD of interest for use in GDM [37,38].”
BackgroundHebert, M., Ma, X., Naraharisetti, S., Krudys, K., Umans, J., Hankins, G., Caritis, S., Miodovnik, M., Mattison, D., Unadkat, J., et al. (2009) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2009.5 · Cited by 252 · cited 1×
“[29] did not detect glyburide in cord serum of infants born to GDM mothers receiving glyburide, apprehensions still exist about the transfer of drug across the placenta even in minimal quantities [39], and also in a recent pharmacokinetic study in GDM patients wherein umbilical cord concentration of drug averaged 70%…”
ResultGlueck, C. J. (2004) · Human Reproduction · doi:10.1093/humrep/deh263 · Cited by 250
Elliott, B. D., Schenker, S., Langer, O., Johnson, R., & Prihoda, T. (1994) · American Journal of Obstetrics and Gynecology · doi:10.1016/0002-9378(94)90078-7 · Cited by 250 · cited 2×
“[29] did not detect glyburide in cord serum of infants born to GDM mothers receiving glyburide, apprehensions still exist about the transfer of drug across the placenta even in minimal quantities [39], and also in a recent pharmacokinetic study in GDM patients wherein umbilical cord concentration of drug averaged 70%…”
BackgroundResultOverweight and obese in gestational diabetes: The impact on pregnancy outcome
Langer, O., Yogev, Y., Xenakis, E. M. J., & Brustman, L. (2005) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2004.12.049 · Cited by 239 · cited 2×
“This may be due to the effects of insulin on lipid metabolism as opposed to control of glucose [46].”
BackgroundResultMetformin vs insulin in the management of gestational diabetes: a meta-analysis
Gui, J., Liu, Q., & Feng, L. (2013) · PLoS ONE · doi:10.1371/journal.pone.0064585 · Cited by 222 · cited 2×
“[15,40], however, our results are more reliable due to its increased sample size.”
ResultIjäs, H., Vääräsmäki, M., Morin-Papunen, L., Keravuo, R., Ebeling, T., Saarela, T., & Raudaskoski, T. (2011) · BJOG: An International Journal of Obstetrics & Gynaecology · doi:10.1111/j.1471-0528.2010.02763.x · Cited by 215 · cited 3×
“Incidence of preterm births reported with metformin use in some of the studies were mostly at 33–35 week of gestation [20,23] which may be an acceptable risk comparing adverse outcomes of hyperglycemia during pregnancy especially in a situation e.”
BackgroundResultPopulation pharmacokinetics of metformin in late pregnancy
Charles, B., Norris, R., Xiao, X., & Hague, W. (2006) · Therapeutic Drug Monitoring · doi:10.1097/01.ftd.0000184161.52573.0e · Cited by 212 · cited 1×
“The main apprehension about the use of metformin in pregnancy is its ability to cross the placenta [36].”
BackgroundNiromanesh, S., Alavi, A., Sharbaf, F. R., Amjadi, N., Moosavi, S., & Akbari, S. (2012) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2012.09.031 · Cited by 203 · cited 1×
“In four studies, blinding was not performed in a double blind fashion [20,22,23,25] while in remaining two, information was not provided completely to assess the risk; therefore the domain of performance bias remained either at high or unclear risk of bias.”
BackgroundRandomized trial of metformin vs insulin in the management of gestational diabetes
Spaulonci, C. P., Bernardes, L. S., Trindade, T. C., Zugaib, M., & Francisco, R. P. V. (2013) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2013.03.022 · Cited by 183 · cited 4×
“Allocation was properly concealed in three studies [20–22] only and in the remaining three [23–25] it remained unclear due to limited information provided by the authors on this domain.”
BackgroundInfluentialTertti, K., Ekblad, U., Koskinen, P., Vahlberg, T., & Rönnemaa, T. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12017 · Cited by 174 · cited 2×
“Risk of Bias Assessment In pool A, sequence generation was performed adequately in five studies [20–24], while in one study it remained unclear [25].”
BackgroundOrnoy, A. (2005) · PubMed · Cited by 172
Perinatal outcomes and the use of oral hypoglycemic agents
Bertini, A. M., Silva, J. C., Taborda, W., Becker, F., Bebber, F. R. L., Viesi, J. M. Z., Aquim, G., & Ribeiro, T. E. (2005) · Journal of Perinatal Medicine · doi:10.1515/jpm.2005.092 · Cited by 161 · cited 2×
“Three of the studies in pool B employed adequate sequence generation methods [28–30], while the remaining four studies did not provide complete information on this domain [26,27,31,32].”
MethodResultNicholson, W., Bolen, S., Witkop, C. T., Neale, D., Wilson, L., & Bass, E. (2009) · Obstetrics & Gynecology · doi:10.1097/aog.0b013e318190a459 · Cited by 161 · cited 1×
“The reviews in the recent past have compared efficacy and safety of metformin and glyburide to insulin wherein randomized controlled trials (RCTs) of both drugs were combined and considered as a single entity [15,16].”
BackgroundDhulkotia, J. S., Ola, B., Fraser, R., & Farrell, T. (2010) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2010.06.044 · Cited by 145 · cited 3×
“[15,40], however, our results are more reliable due to its increased sample size.”
BackgroundResultMoore, L. E., Briery, C. M., Clokey, D., Martin, R. W., Williford, N. J., Bofill, J. A., & Morrison, J. C. (2007) · PubMed · Cited by 123
Infant Overweight Is Associated with Delayed Motor Development
Slining, M., Adair, L. S., Goldman, B. D., Borja, J. B., & Bentley, M. (2010) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2009.12.054 · Cited by 122 · cited 2×
“Later in life, such infants are at risk for disease conditions such as delayed motor development, premenopausal breast cancer, obesity and diabetes [8–11].”
BackgroundAnjalakshi, C., Balaji, V., Balaji, M. S., & Seshiah, V. (2006) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2006.09.031 · Cited by 104 · cited 4×
“Three of the studies in pool B employed adequate sequence generation methods [28–30], while the remaining four studies did not provide complete information on this domain [26,27,31,32].”
BackgroundMethodResultInfluentialLain, K. Y., Garabedian, M. J., Daftary, A., & Jeyabalan, A. (2009) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2009.02.038 · Cited by 100 · cited 1×
“We observed attrition bias in four studies [26,28,30,31], while three studies had complete outcome data [27,29,32].”
ResultBorderline gestational diabetes mellitus and pregnancy outcomes
Ju, H., Rumbold, A. R., Willson, K. J., & Crowther, C. A. (2008) · BMC Pregnancy and Childbirth · doi:10.1186/1471-2393-8-31 · Cited by 100
Neonatal Hypoglycaemia in Infants of Diabetic Mothers given Sulphonylurea Drugs in Pregnancy
Kemball, M. L., McIver, C., Milner, R. D. G., Nourse, C. H., Schiff, D., & Tiernan, J. R. (1970) · Archives of Disease in Childhood · doi:10.1136/adc.45.243.696 · Cited by 94 · cited 1×
“Concern about the use of OADs in pregnancy is mostly related to first generation sulfonylurea drugs, which were reported to increase risk for fetal anomalies and neonatal hypoglycemia [34,35].”
BackgroundThe use of glyburide in the management of gestational diabetes mellitus: A meta-analysis
Zeng, Y.-C., Li, M.-J., Chen, Y., Jiang, L., Wang, S.-M., Mo, X.-L., & Li, B.-Y. (2014) · Advances in Medical Sciences · doi:10.1016/j.advms.2014.03.001 · Cited by 76 · cited 1×
“[48] Studies that formed the basis of the analysis were consistent for the majority of outcomes and heterogeneity remained non-significant except for very few outcomes.”
BackgroundComparison of Glyburide versus Insulin in Management of Gestational Diabetes Mellitus
Ogunyemi, D. A., Jesse, M., & Davidson, M. (2007) · Endocrine Practice · doi:10.4158/ep.13.4.427 · Cited by 74 · cited 1×
“We observed attrition bias in four studies [26,28,30,31], while three studies had complete outcome data [27,29,32].”
ResultGlyburide as treatment option for gestational diabetes mellitus
Tempe, A., & Mayanglambam, R. D. (2013) · Journal of Obstetrics and Gynaecology Research · doi:10.1111/jog.12042 · Cited by 71 · cited 3×
“Three of the studies in pool B employed adequate sequence generation methods [28–30], while the remaining four studies did not provide complete information on this domain [26,27,31,32].”
BackgroundMethodResultThrough the Looking Glass at Early-Life Exposures and Breast Cancer Risk
Forman, M. R., Cantwell, M. M., Ronckers, C. M., & Zhang, Y. (2005) · Cancer Investigation · doi:10.1080/07357900500283093 · Cited by 69
Suspected macrosomia? Better not tell
Sadeh-Mestechkin, D., Walfisch, A., Shachar, R., Shoham‐Vardi, I., Vardi, H., & Hallak, M. (2008) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-008-0566-y · Cited by 49 · cited 1×
“We considered lack of blinding a serious threat for validity of data for these outcomes as increase in rate of suspected macrosomia was reported to be linked with increase in risk of these two outcomes also [33].”
BackgroundJovanovic‐Peterson, L., Kitzmiller, J. L., & Peterson, C. M. (1992) · American Journal of Obstetrics and Gynecology · doi:10.1016/s0002-9378(11)91710-4 · Cited by 43 · cited 1×
“Maternal hyperglycemia is mainly linked with increased risk of large babies and neonatal hypoglycemia, but in our study the difference between the two groups remained nonsignificant for maternal glycemic levels [44,45].”
BackgroundGlibenclamida no tratamento do diabete melito gestacional em estudo comparado à insulina
Silva, J. C., Bertini, A. M., Taborda, W., Becker, F., Bebber, F. R. L., Aquim, G. M. D. C., & Viesi, J. M. Z. (2007) · Arquivos Brasileiros de Endocrinologia & Metabologia · doi:10.1590/s0004-27302007000400007 · Cited by 42
VANKY, E., DE ZEGHER, F., DÍAZ, M., IBÁÑEZ, L., & CARLSEN, S. M. (2012) · Acta Obstetricia et Gynecologica Scandinavica · doi:10.1111/aogs.12015 · Cited by 32 · cited 1×
“Nevertheless, results of an earlier study in polycystic ovary syndrome (PCOS) patients reported a decreased incidence of preterm deliveries in comparison to placebo [42].”
ResultUse of Chlorpropamide in the Treatment of Diabetes in Pregnancy
Douglas, C. P., & Richards, R. D. (1967) · Diabetes · doi:10.2337/diab.16.1.60 · Cited by 25
Research works printed but not linked: 1
- 2013, Gestational diabetes mellitus: Clinical management guidelines for obstetricians–gynecologists, Obstet Gynecol, 122, 406
Cited by
ACOG Practice Bulletin No. 190: Gestational Diabetes Mellitus
(2018) · Obstetrics & Gynecology · doi:10.1097/aog.0000000000002501 · Cited by 1,820
Practice Bulletin No. 183: postpartum hemorrhage
(2017) · Obstetrics & Gynecology · doi:10.1097/aog.0000000000002351 · Cited by 1,406
A Clinical Update on Gestational Diabetes Mellitus
Sweeting, A., Wong, J., Murphy, H. R., & Ross, G. P. (2022) · Endocrine Reviews · doi:10.1210/endrev/bnac003 · Cited by 928
Blonde, L., Umpierrez, G. E., Reddy, S. S., McGill, J. B., Berga, S. L., Bush, M., Chandrasekaran, S., DeFronzo, R. A., Einhorn, D., Galindo, R. J., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.08.002 · Cited by 507
ACOG Practice Bulletin No. 201: Pregestational Diabetes Mellitus
(2018) · Obstetrics & Gynecology · doi:10.1097/aog.0000000000002960 · Cited by 470
Metadata
- Authors
- Poolsup, N., Suksomboon, N., & Amin, M.
- Affiliations
- Silpakorn University (TH)
- Mahidol University (TH)
- Corresponding author
- Suksomboon, Naeti
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2014-10-10
- Volume
- 9
- Issue
- 10
- Pages
- e109985
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC4193853
- OpenAlex
- W2041276822
- Cited by
- 107
- References
- 49
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 3 · 2023: 15 · 2022: 8 · 2021: 30 · 2020: 4 · 2019: 9 · 2018: 14 · 2017: 9 · 2016: 5 · 2015: 7
- FWCI
- 1.12
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Greater South Information System
- Topics
- Health Sciences › Medicine › Obstetrics and Gynecology › Gestational Diabetes Research and Management
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Pregnancy and Medication Impact
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- gestational diabetes mellitus, oral antidiabetic drugs, metformin, glibenclamide, insulin therapy, preterm birth, gestational hypertension, macrosomia, neonatal hypoglycemia, postprandial blood glucose, drug safety
- MeSH terms
- Female, Glyburide, Humans, Hypoglycemic Agents, Insulin, Metformin, Pregnancy, Diabetes, Gestational, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.